ORIGINAL ARTICLE. patients with advanced head and neck cancer. Studies have demonstrated
|
|
- Scott Reed
- 6 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE Characteristics Associated With Swallowing Changes After Concurrent Chemotherapy and Radiotherapy in Patients With Head and Neck Cancer Joseph K. Salama, MD; Kerstin M. Stenson, MD; Marcy A. List, PhD; Loren K. Mell, MD; Ellen MacCracken, MS; Ezra E. Cohen, MD; Elizabeth Blair, MD; Everett E. Vokes, MD; Daniel J. Haraf, MD Objective: To define factors that acutely influenced swallowing function prior to and during concurrent chemotherapy and radiotherapy. Design: A summary score from 1 to 7 (the swallowing performance status scale [SPS]) of oral and pharyngeal impairment, aspiration, and diet, was assigned to each patient study by a single senior speech and swallow pathologist, with higher scores indicating worse swallowing. Generalized linear regression models were formulated to asses the effects of patient factors (performance status, smoking intensity, amount of alcohol ingestion, and age), tumor factors (primary site, T stage, and N stage), and treatment-related factors (radiation dose, use of intensity-modulated radiation therapy, response to induction chemotherapy, postchemoradiotherapy neck dissection, and preprotocol surgery) on the differences between SPS score before and after treatment. Setting: University hospital tertiary care referral center. Patients: The study included 95 patients treated under a multiple institution, phase 2 protocol who underwent a videofluorographic oropharyngeal motility (OPM) study to assess swallowing function prior to and within 1 to 2 months after the completion of concurrent chemotherapy and radiotherapy. Main Outcome Measures: Factors associated with swallowing changes after chemoradiotherapy. Results: The mean pretreatment and posttreatment OPM scores were 3.09 and 3.77, respectively. Patients with T3 or T4 tumors (odds ratio [OR], 0.38; 95% confidence interval [CI], ; P=.04) and a performance status of 1 or 2 (OR, 0.37; 95% CI, ; P=.03) were less likely to have worsening of swallowing after chemoradiotherapy. There was a trend for worse swallowing with increasing age (OR, 1.04; 95% CI, ; P=.08). Only T stage (T3 or T4) was associated with improved swallowing after treatment (OR, 8.96; 95% CI, ; P.001). Conclusion: In patients undergoing concurrent chemotherapy and radiotherapy, improved swallowing function over baseline is associated with advanced T stage. Arch Otolaryngol Head Neck Surg. 2008;134(10): Author Affiliations: Department of Radiation and Cellular Oncology (Drs Salama, Mell, Vokes, and Haraf), Section of Otolaryngology Head and Neck Surgery (Drs Stenson and Blair and Ms MacCracken), Cancer Research Center (Drs Salama, Stenson, List, Cohen, Blair, Vokes, and Haraf), Center for Speech and Swallowing Disorders (Ms MacCracken), and Section of Hematology/Oncology (Drs Cohen and Vokes), University of Chicago, Chicago, Illinois. DYSPHAGIA IS COMMON IN patients with advanced head and neck cancer. Studies have demonstrated that 38% of patients present with mild-moderate to moderate-severe swallowing impairment. 1 In addition, patients with hypopharyngeal and laryngeal primary tumors have been found to have worse swallowing at presentation. 1 While previous investigations have documented severity of dysphagia after definitive or adjuvant radiation therapy or concomitant chemoradiotherapy, 2,3 few studies have documented swallowing function changes from baseline in patients treated with concurrent chemotherapy and radiotherapy. Of the studies that have reported changes in swallowing function from baseline, most have focused on alterations occurring in the swallowing mechanism. New delayed initiation of the swallow trigger, uncoordinated timing of bolus propulsion, opening of the pharyngoesophageal segment, closure of the larynx, tongue base retraction, and vestibular penetration of barium have all been reported following concurrent chemotherapy and radiotherapy. 4-6 Additionally, increase from baseline in time to velopharyngeal and laryngeal closure and decreased oropharyngeal swallow efficiency have been reported. 7 While identification of changes in the swallowing mechanism are important to aid in therapeutic intervention for patients undergoing concurrent chemotherapy and radiotherapy, so is the identification of factors predicting improvement or decrement in swallowing function. Therefore, in this study, we sought to identify factors that influenced changes in swallowing during a course of concurrent chemotherapy and radiotherapy. 1060
2 METHODS From November 1998 to August 2002, 222 patients with stage III or IV advanced head and neck cancer were treated under a multipleinstitution, phase2protocolofconcurrentchemotherapy and radiotherapy. Organ preservation was the primary goal of the treatment protocol. Resection of small tonsillar or oral cavity primary tumors was allowed, as was pretherapy modified radical neck dissections. Two 21-day cycles of induction paclitaxel (135 mg/m 2 over 3 hours) and carboplatin (area under the curve, 2; given after paclitaxel) were followed by 4 cycles (for resected cases) or 5 cycles (for unresected cases) of concurrent chemotherapy and radiotherapy. Each chemoradiotherapy cycle consisted of 1 weekly dose of paclitaxel (100 mg/m 2 after the first dose of radiation), continuous infusion fluorouracil (600 mg/ m 2 for 5 days), oral hydroxyurea (500 mg every 12 hours for 6 days), and twice daily radiation therapy (1.5 Gy per fraction with a minimum 6-hour interfraction interval) followed by a 9-day break. The total radiation dose to gross disease was initially 75 Gy, but later decreased to 72 to 75 Gy based on the response to induction chemotherapy. Initially patients were treated with 3-dimensional conformal radiotherapy, but later some patients were treated with intensity-modulated radiotherapy (IMRT). Following the completion of concurrent chemotherapy and radiotherapy, patients with N2 or higher-stage neck disease underwent a planned neck dissection. Details of the protocol have been outlined previously. 8 Of the 222 patients enrolled, 132 eligible patients were treated at our institution. Our study population consisted of 95 of the 132 who had swallowing function assessed both prior to the initiation of concurrent chemotherapy and radiotherapy and within 1 to 2 months after the completion of chemoradiotherapy. Each assessment consisted of an anterior and lateral videofluorographic OPM study, as described previously. 9,10 Briefly, a recording was made by the speech pathologist while patients swallowed small amounts of liquid barium, paste barium, and a barium-coated cookie. Slow motion, frame-by-frame analysis was used to evaluate oral, pharyngeal, laryngeal, and cricopharyngeal function. In addition, attention was given to the presence and cause of aspiration as well as laryngeal sensitivity, response to therapeutic techniques, and percentage aspiration. Multiple components of swallowing were summarized on the OPM record and recorded in a computerized database storage and reporting system, as described previously. 1 Using this standardized format, interrater variability was low, and intrarater variability nonexistent because all studies were conducted at the University of Chicago Speech and Swallowing Center by the senior speech pathologist (E.M.) for reliable and consistent reporting. A sample OPM report is provided as Figure 1. Individualized therapy was provided based on the results of the OPM study and directed to specific disorders documented during the videofluorographic procedure. In addition, therapeutic techniques were applied during the OPM study to assess response to maneuvers and change in swallow physiology and aspiration. Patients were provided with base-of-thetongue and laryngeal motility exercises, which they were encouraged to perform during treatment. A safe oral diet with a variety of food textures based on OPM results was encouraged with the goal of maintaining optimal flexibility and range of motion of pharyngeal structures. Changes in patient swallowing were defined in 2 ways: (1) worsening of swallowing was defined as a posttherapy swallowing performance scale (SPS) score higher than the pretherapy SPS score; (2) improvement in swallowing was defined as a posttherapy SPS score lower than the pretherapy score. The SPS score is a summary score from 1 to 7 of oral impairment, pharyngeal impairment, aspiration, and diet, with higher scores indicating worse swallowing, as outlined in Table 1. This rating scale is designed to summarize the clinical results of the OPM study, and the score provides an overall clinical picture of swallowing function. Because reliable SPS results depend on skilled clinical interpretation, the score is not an additive or formulaic summary. For each patient, the SPS score prior to and following concurrent chemotherapy and radiotherapy was extracted from the OPM report. Generalized linear modeling was used to model changes in the logspsscore.backwardstepwiselogisticregression(p.10threshold) was used to model improved or worsened swallowing. Covariates included patient factors (performance status, smoking intensity, amount of alcohol ingestion, and age), tumor factors (primary site, T stage, and N stage), and treatment-related factors (radiationdose, useofimrt, responsetoinductionchemotherapy, and preprotocol surgery). Statistical analysis was conducted using Stata 7.0 software (StataCorp LP, College Station, Texas). RESULTS Clinicopathologic characteristics are summarized in Table 2, while treatment-related characteristics are summarized in Table 3. Most of the patients had a good performance status (Eastern Cooperative Oncology Group [ECOG] score, 0-1), laryngeal (23%; n=22) or oropharyngeal primary tumors (52%; n=49), advanced T stage (57% T3 or T4; n=54), and advanced nodal disease (75% N2 or N3; n=54). Furthermore, 92% of patients did not have prior surgery (n=87), and 80% had a response to induction chemotherapy (n=76). When compared with patients treated on the same protocol but not included in this analysis, our patients were more likely to have been treated with IMRT (57% [n=54] vs 34%) (P.01) and to have an ECOG performance status of 0 (57% [n=51] vs 24%) (P.01). Otherwise, there were no statistical differences among patients included and other patients. In general, swallowing function decreased from baseline in patients after concurrent chemotherapy and radiotherapy. Specifically, 59 patients had a worse SPS score after treatment (60%), 17 had no change in their SPS score (17%), and 19 had an improvement in their SPS score (19%). The mean pretreatment SPS score was 3.09, and the mean posttreatment SPS score was 3.77 (P.01 by the Wilcoxon test). As listed in Table 4 and illustrated in Figure 2, for 82% of patients whose swallowing changed, for worse or better (n=78), the change was only 1 to 2 points on the SPS scale. The median and mean change values during chemoradiotherapy were 1 and 1.7 points (range, 1-5 points), respectively. Most patients with laryngeal primary tumors had T3 (14%; n=3) or T4 (82%; n=18) tumors. When patients with laryngeal cancer were analyzed separately, the mean pretreatment SPS score was 4.3 (range, 1-7), and the mean posttreatment SPS score was 4.2 (range, 2-7). While 4 patients had no change in their swallowing after chemoradiotherapy, 10 had a decrement, and 8 had improvement in their swallowing. The median and mean changes in swallowing scores were 0 and 0.1 (range, 0-5), respectively. When factors associated with worsening of swallowing were analyzed, only a trend for worse swallowing with increasing age was found (odds ratio [OR], 1.04; 95% confidence interval [CI], ) (P=.08). Surprisingly, patients with T3 or T4 tumors (OR, 0.38; 95% CI, 1061
3 THE UNIVERSITY OF CHICAGO Center for Speech and Swallowing Disorders Oropharyngeal Motility (OPM) Study Data Entry Form UNIT # NAME PHYSICIAN TAPE # BIRTHDAY 1 VISIT# AGE CLINICIAN TYPE INS. 1. Rationale for the Study, Brief History Notes STUDY DATE CONSENT DATE SYMPTOM ONSET TX ONSET 12/20/99 REPORT DATE OBSERVATIONS 2. Current Diet 10. Reflex Time 17. Cerv. Esoph. 0 = Non PO 1 = Liquid 2 = Soft 0 = No reflex 1 = Normal 1 = Dilation 2 = Fistula 3 = Pureed 4 = Normal 2 = Delayed 3 = Zenkers 4 = Reflux + = Other 3. % Intake via #2 4. Tube in Use 0 = None 1 = NG Tube 2 = G Tube 3 = J Tube 4 = IV 5. Oral Prep Impairment 0 = Normal 2 = Moderate 0 = Normal 2 = Moderate 1 = Mild 3 = Severe 11. Reflex Strength 0 = No reflex 1 = Weak 2 = Adequate 3 = Normal 12. Pharyngeal Impairment 0 = Normal 2 = Moderate 6. Oral Prep Problems 13. Pharyngeal 1 = Bolus hold 1 = Prolonged transit time 2 = Bolus form 3 = Mastication 2 = Laryngeal elevation 4 = Lip closure 5 = Suckle lag 3 = Velar elevation 6 = Nipple hold 4 = Laryngeal closure 7 = Aversive Behaviors 5 = Vallecular stasis + = Other (below) 6 = Pyriform stasis 7 = Reduced peristalsis 8 = Suck/swallow ratio 9 = Swallow/resp. coordination 7. Oral Impairment + = Other (below) 1 = Mild 3 = severe 8. Oral Problems 1 = Poor bolus control 2 = Piecemeal deglutition 3 = Prolonged transit time 4 = Oral stasis 5 = Poor suck rate 6 = Poor suck amplitude 7 = Poor suck maintenance 8 = Poor tongue coordination + = Other (below) 9. Oral Transit Time (seconds) 14. Pharyngeal Symmery 0 = Normal 1 = bolus to right 2 = bolus to left 15. Pharyngeal Transit Time (seconds) 16. Cerv. Esoph. Impairment 0 = normal 2 = moderate 1 = Mild 3 = Severe 1 = mild 3 = severe 18. Aspiration 0 = Nose (skip below) 1 = Pre-reflex 2 = Mid-reflex 3 = Post-reflex 19. Asp. Location 1 = Laryngeal vestibule 2 = Trachea 20. Asp. Sensitivity 1 = good 2 = fair 3 = poor 21. % Aspiration 22. Response to Therapy Technique 1 = good 2 = fair 3 = poor 23. Material Asp. 0 = All 1 = Liquid 2 = Paste 3 = Cookie + = Other (below) 24. Follow-up 25. Suction Needed 26. Suction Provided 27. Swallowing Perfomance Status Scale 1. Normal 2. WFL - abnormal oral or pharyngeal stage but able to eat regular diet without modifications or swallowing precautions. 3. Mild impairment - mild dysfunction in oral or pharyngeal stage. Requires modified diet or therapeutic swallowing precautions. 4. Mild-moderate impairment - need for therapeutic precautions - mild dysfunction in oral or pharyngeal stage, requires modified diet and therapeutic precautions to minimize aspiration risk. 5. Moderate impairment - moderate dysfunction in oral or pharyngeal stage, aspiration noted on exam, requires modified diet and swallowing precautions to minimize risk of aspiration. 6. Moderate-severe dysfunction - requires supplemental central feeding support - moderate dsyfunction is oral or pharyngeal stage, Aspiration noted on exam, requires modified diet and swallowing precaution to minimize risk of aspiration, needs supplemental enteral feeding support. 7. Severe impairment - severe dysfunction with significant aspiration or inadequate oropharyngeal transit to esophagus, NPO, requires primary enteral feeding support. 28. Recommended Diet 0 = General diet. 1 = Mechanical soft diet. 2 = Supraglottic diet. 3 = Puree diet. 4 = Liquid only. 30. Additional Recommendations (be brief and concise) RECOMMENDATIONS 29. Swallowing Precautions 5 = Thick liquids only. 0. No precautions needed. 6 = Thick warm liquids only. 1. Upright pos. (45 degree angle). 7 = Thin cold liquids only. 2. 1/2 to 1 tsp/swallow. 8 = No liquids. 3. Eat slowly (empty mouth between each bolus). 4. Double swallow. 5. Alternate consistencies. 6. Cough/swallow occasionally. 7. Supraglottic swallow. 8. Thermal stim times. 9. Chin tuck position. A. Stay upright min after meal. B. Mendelsohn maneuver. C. Low flow nipple. D. Fast flow nipple. E. Frequent rest periods. F. Straight upper body support. G. Instruct caregiver. H. Postural adjustments (see below). Figure 1. Oropharyngeal motility study data entry form. 1062
4 Table 1. Swallowing Performance Status Scale Score Severity Description 1 Normal swallowing Normal swallowing 2 Within functional limits Abnormal oral or pharyngeal stage; able to eat regular diet without modifications or swallowing precautions 3 Mild impairment Mild dysfunction in oral or pharyngeal stage; requires modified diet without need for therapeutic swallowing precautions 4 Mild-moderate impairment 5 Moderate impairment 6 Moderate-severe dysfunction Need for therapeutic precautions; requires modified diet and therapeutic precautions to minimize aspiration risk Moderate dysfunction in oral or pharyngeal state; aspiration noted on examination; requires modified diet and swallowing precautions to minimize risk of aspiration Requires supplemental enteral feeding support; moderate dysfunction in oral or pharyngeal stage; aspiration noted on examination; requires modified diet and swallowing precautions to minimize risk of aspiration; needs supplemental feeding support 7 Severe impairment Severe dysfunction with significant aspiration or inadequate oropharyngeal transit to esophagus; nothing by mouth; requires primary enteral feeding support ) (P=.04) and an ECOG performance status of 1 to 2 (OR, 0.37; 95% CI, ) (P=.03) were less likely to have worse swallowing after a course of concurrent chemotherapy and radiotherapy. Only advanced T stage (T3 or T4 tumors) was associated with improved swallowing after chemoradiotherapy (OR, 8.96; 95% CI, ) (P.001). A total of 51 patients had gastrostomy tubes placed before, during, or within 6 months of the completion of concurrent chemotherapy and radiotherapy (54%). This included 11 patients with gastrostomy tube placement prior to the initiation of protocol treatment (12%), 36 patients with gastrostomy tubes placed during the course of concurrent chemotherapy and radiotherapy (38%), and 4 had gastrostomy tube placement within 6 months of completing concurrent chemotherapy and radiotherapy (4.2%). At final follow-up, 12 patients had gastrostomy tubes in place (13%), and 77 patients were free of gastrostomy tubes (81%). In the remaining 6 patients, information on gastrostomy tube status was not available. COMMENT Multiple studies have demonstrated improved locoregional control and in some cases survival with definitive or adjuvant chemoradiotherapy over radiotherapy As Table 2. Clinicopathologic Characteristics a Characteristic Patients, No. (%) Performance status 0 51 (54) 1 42 (44) 2 2 (2) Primary tumor site Oral cavity 8 (8) Oropharynx 49 (52) Nasopharynx 4 (4) Hypopharynx 5 (5) Larynx 22 (23) Other 7 (7) T stage Tx 7 (7) T1 15 (16) T2 19 (20) T3 16 (17) T4 38 (40) N stage N0 14 (15) N1 12 (13) N2a 14 (15) N2b 21 (22) N2c 19 (20) N3 15 (16) a The median (range) patient age was 58 (35-77) years. Table 3. Treatment-Related Factors a Characteristic Patients, No. (%) IMRT Yes 54 (57) No 41 (43) Response to induction CTX CR 29 (31) PR 47 (50) SD 6 (6) Unevaluable 13 (14) Surgery preprotocol Yes 8 (8) No 87 (92) Abbreviations: CR, complete response; CTX, chemotherapy; IMRT, intensity-modulated radiation therapy; PR, partial response; SD, stable disease. a The mean (range) radiation dose was 72.5 ( ) Gy. Table 4. Absolute Change in SPS Score Absolute Difference in SPS Score Patients, No. (%) 0 17 (18) 1 44 (46) 2 20 (21) 3 10 (11) 4 2 (2) 5 2 (2) Abbreviation: SPS, swallowing performance status scale (a summary score from 1 to 7). control and survival continue to improve in patients with advanced head and neck cancer, functional, cosmetic, and quality-of-life issues become more important. While con- 1063
5 Patients, No SPS Score Change Figure 2. Frequency of change in swallowing performance status scale (SPS) score (SPS score before treatment minus SPS score after treatment). Improvement in swallowing is indicated by a positive value, worsening by a negative value. trol is improved with concurrent chemotherapy and radiotherapy, rates of dysphagia are also higher, as seen in the report of Radiation Therapy Oncology Group (RTOG) in which 23% of patients treated with concomitant cisplatin and radiotherapy were able to swallow only soft foods compared with 9% of patients receiving sequential cisplatin/fluorouracil irradiation and 15% of patients receiving radiotherapy alone. Quality-of-life studies demonstrate that for patients with advanced head and neck cancer, difficulties and embarrassment caused by eating in public, distorted speech, hoarseness, and mouth pain are important predictors of overall quality of life. 15 Furthermore, after being cured of my cancer and living as long as possible, patients prioritize being able to swallow all foods and liquids only behind having no pain, returning to regular activities, and having a normal amount of energy. Given the high level of importance that patients place on swallowing, we sought to determine in this study the factors that could predict detrimental or improved swallowing outcomes following a course of chemoradiotherapy. One of the interesting findings from our study populationwasthepreservationoffunctioninpatientswithadvanced laryngeal cancer. Recent reports demonstrate that patients with larynx cancer treated with concurrent chemotherapy and radiotherapy had improved quality of life over surgically treated patients and that patients with an intact larynx were morelikelytoobtainnutritionorallywithoutsupplements. 16 Furthermore, patients with advanced larynx cancer treated withconcurrentchemotherapyandradiotherapywerefound to have intelligible communication and efficient swallowing. 6 Our analysis demonstrated that patients with laryngeal cancer had a worse mean baseline swallowing score than the entire study population. However, after treatment, these patients had little change in their swallowing score compared with a mean decrement of 0.78 in the population as a whole. These results indicate that patients with advanced laryngeal cancer treated with concurrent chemotherapy and radiotherapy may be able to preserve swallowing function. Perhaps the most interesting finding from this analysis is that patients with more advanced T stages were less likely to have worsened swallowing and more likely to have improved swallowing after a course of concurrent chemotherapy and radiotherapy. To our knowledge, this has not been reported in the literature. Our group s prior investigations with pretherapy swallowing studies revealed no association between T stage and aspiration status, cervical esophageal impairment, pharyngeal impairment, oral impairment, and SPS score. 1 Other investigators have not found an association between T stage and dysphagia, but the population studied was heterogeneous and included patients treated with definitive and adjuvant radiation and chemoradiation. 2,17 Our finding that patients with advanced T stages were less likely to have worsening of their swallowing and more likely to have improved swallowing will aid practitioners in counseling patients as to expectations during treatment. However, it must be noted that patients were strongly encouraged to maintain oral intake as long as possible during treatment and did not undergo routine percutaneous endoscopic gastrostomy tube placement. This strategy was used to encourage patients to exercise the swallowing mechanism throughout treatment. Our investigation found no correlation between the use of IMRT and swallowing dysfunction. However, this is not surprising, since our main goal of IMRT was to decrease the dose to the parotid glands, skin, larynx, and oral cavity, while no attempt was made to spare the pharyngeal constrictors owing to their close proximity to the retropharyngeal nodal region. Other investigators have found that radiation dose to the upper, middle, and lower pharyngeal constrictors and the supraglottic and glottic larynx have been associated with swallowing dysfunction. 18 Preliminary results from patients treated prospectively with IMRT to spare these structures demonstrated statistically significant correlations between aspiration risk and partial volumes of the pharyngeal constrictors and glottic and supraglottic larynx receiving radiation doses between 50 and 65 Gy. Furthermore, dose to the pharyngeal constrictors was associated with stricture risk and worsening of liquid and solid swallowing. 19 We are currently investigating the interactions of chemotherapy and IMRT in regard to swallowing function, neck fibrosis, and saliva flow. Patients analyzed in the present study were more likely to have been treated with IMRT, which may enhance the applicability of these results because 76% to 82% of practitioners are currently using IMRT to treat patients with head and neck cancer. 20 These data indicate that 54% of patients required gastrostomy tube nutritional assistance during the course of or shortly after concurrent chemotherapy and radiotherapy (n=51). These numbers are consistent with the entire protocol cohort from which these patients were drawn in which 62% of patients had gastrostomy tubes placed prior to (26%) or during (36%) the course of chemoradiotherapy. However, at final follow-up, only 13% had gastrostomy tubes in place (n=12). This is probably owing to many causes, the first of which is that patients with gastrostomy tubes in place are more likely to have multiple swallowing assessments and therefore would have data making them eligible for this analysis. Furthermore, mucosal healing and swallowing therapy enable patients to regain swallowing function. Our study is limited by the retrospective nature of the analysis as well as the short follow-up period. The goal of 1064
6 this study was only to assess what factors were associated with swallowing changes during a course of chemoradiotherapy. Swallowing function for these patients will continue to evolve with longer follow-up. Furthermore, the tools used to assess swallowing limit the analysis. The SPS itself has not been validated by statistical analysis; rather, it is a quick, clinically relevant scoring system for patients with head and neck cancer and a simple, single-step technique for classifying swallowing functional status. While other more specific measures are available to score videofluorographic swallowing test results (eg, oropharyngeal swallow efficiency), these methods are extremely labor intensive and are best suited for the laboratory setting. By design, our study was only intended to assess acute swallowing changes of concurrent chemotherapy and radiotherapy. Further investigation will be needed to determine long-term swallowing changes. However, all the patient data was collected prospectively by a single senior speech pathologist (E.M.). Furthermore, all patients described in this study were managed uniformly with organ-preserving intent by an experienced multidisciplinary team of head and neck surgeons, medical oncologists, and a single radiation oncologist(d.j.h.). The value of the SPS might have been more limited if it had been administered by multiple raters, with subjective scoring changes leading to interobserver variability. However, because all of the OPM findings were interpreted by a single senior speech pathologist, our data were obtained without interobserver variability. To validate these conclusions, we plan on expanding our data set with patients treated at our institution with similar chemoradiotherapy regimens. In addition, swallowing function continues to change over time in patients treated with chemoradiotherapy for head and neck cancer. Therefore, we plan to determine which factors are associated with chronic swallowing function changes and esophageal stricture. In conclusion, we found that patients with advanced T stages (T3 and T4) and worse performance status (ECOG 1 and 2) were less likely to have worsening of swallowing during a course of concurrent chemotherapy and radiotherapy. Additionally, patients with T3 or T4 tumors were more likely to have an improvement in swallowing function after the completion of their treatment. Patients with advanced laryngeal tumors, while initially presenting with worse swallowing function, had less of a decrement in swallowing function after chemoradiotherapy. Submitted for Publication: October 15, 2006; final revision received October 24, 2007; accepted October 30, Correspondence: Joseph K. Salama, MD, Department of Radiation and Cellular Oncology, 5758 S Maryland Ave, MC 9006, Chicago, IL (jsalama@radonc.uchicago.edu). Author Contributions: Dr Salama had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Salama, List, Mell, Blair, Vokes, and Haraf. Acquisition of data: Salama, Stenson, Mell, MacCracken, Cohen, Blair, and Vokes. Analysis and interpretation of data: Salama, Stenson, List, Mell, Cohen, and Haraf. Drafting of the manuscript: Salama, Mell, Vokes, and Haraf. Critical revision of the manuscript for important intellectual content: Salama, Stenson, List, Mell, MacCracken, Cohen, Blair, Vokes, and Haraf. Statistical analysis: Mell. Administrative, technical, and material support: Stenson, List, MacCracken, Cohen, Blair, Vokes, and Haraf. Study supervision: Salama, Stenson, List, Cohen, and Haraf. Financial Disclosure: None reported. PreviousPresentation: Thisarticlewaspresentedatthe2006 AmericanHeadandNeckSocietyAnnualMeeting&Research Workshop; August 18, 2006; Chicago, Illinois. REFERENCES 1. Stenson KM, MacCracken E, List M, et al. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000; 126(3): Nguyen NP, Moltz CC, Frank C, et al. Dysphagia severity following chemoradiation and postoperative radiation for head and neck cancer. Eur J Radiol. 2006; 59(3): Smith RV, Goldman SY, Beitler JJ, Wadler SS. Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organsparing protocol for advanced pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2004;130(7): Graner DE, Foote RL, Kasperbauer JL, et al. Swallow function in patients before and after intra-arterial chemoradiation. Laryngoscope. 2003;113(3): Eisbruch A, Lyden T, Bradford CR, et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for headand-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53(1): Carrara-de Angelis E, Feher O, Barros AP, Nishimoto IN, Kowalski LP. Voice and swallowing in patients enrolled in a larynx preservation trial. Arch Otolaryngol Head Neck Surg. 2003;129(7): Logemann JA, Rademaker AW, Pauloski BR, et al. Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. Head Neck. 2006;28(1): Haraf DJ, Rosen FR, Stenson K, et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003;9(16, pt 1): Logemann JA, Bytell DE. Swallowing disorders in three types of head and neck surgical patients. Cancer. 1979;44(3): Lazarus C, Logemann JA, Gibbons P. Effects of maneuvers on swallowing function in a dysphagic oral cancer patient. Head Neck. 1993;15(5): Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22): Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19): Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19): Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1): List MA, Siston A, Haraf D, et al. Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination. J Clin Oncol. 1999;17(3): Fung K, Lyden TH, Lee J, et al. Voice and swallowing outcomes of an organpreservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys. 2005;63(5): Nguyen NP, Frank C, Moltz CC, et al. Impact of dysphagia on quality of life after treatment of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005;61(3): Eisbruch A, SchwartzM, RaschC, etal. Dysphagiaandaspirationafterchemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys. 2004;60(5): Eisbruch A. Intensity-modulated radiotherapy (IMRT) aiming to reduce dysphagia: early dose-effect correlations. Paper presented at: American Head and Neck Society 2006 Annual Meeting & Research Workshop on the Biology, Prevention, & Treatment of Head & Neck Cancer; August 18, 2006; Chicago, IL. 20. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., Cancer. 2005;104(6):
SITE OF DISEASE AND TREATMENT PROTOCOL AS CORRELATES OF SWALLOWING FUNCTION IN PATIENTS WITH HEAD AND NECK CANCER TREATED WITH CHEMORADIATION
SITE OF DISEASE AND TREATMENT PROTOCOL AS CORRELATES OF SWALLOWING FUNCTION IN PATIENTS WITH HEAD AND NECK CANCER TREATED WITH CHEMORADIATION Jeri A. Logemann, PhD, 1,3 Alfred W. Rademaker, PhD, 2,3 Barbara
More informationLaryngeal Conservation
Laryngeal Conservation Sarah Rodriguez, MD Faculty Advisor: Shawn Newlands, MD, PhD The University of Texas Medical Branch Department of Otolaryngolgy Grand Rounds Presentation February 2005 Introduction
More informationDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston Texas.
ORIGINAL ARTICLE Gastrostomy tube placement in patients with hypopharyngeal cancer treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence Mihir K. Bhayani, MD, Katherine
More informationSwallow Preservation Exercises during Chemoradiation Therapy Maintains Swallow Function
Original Research Head and Neck Surgery Swallow Preservation Exercises during Chemoradiation Therapy Maintains Swallow Function Otolaryngology Head and Neck Surgery 149(6) 878 884 Ó American Academy of
More informationAccepted 12 August 2010 Published online 15 December 2010 in Wiley Online Library (wileyonlinelibrary.com). DOI: /hed.21624
ORIGINAL ARTICLE IMPACT OF EARLY PERCUTANEOUS ENDOSCOPIC GASTROSTOMY TUBE PLACEMENT ON NUTRITIONAL STATUS AND HOSPITALIZATION IN PATIENTS WITH HEAD AND NECK CANCER RECEIVING DEFINITIVE CHEMORADIATION THERAPY
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationSwallowing after a Total Laryngectomy
Swallowing after a Total Laryngectomy Diane Longnecker, M.S.,CCC-SLP, BCS-S Baylor Institute for Rehabilitation at Baylor University Medical Center Dallas, TX Disclosure Statement No relevant financial
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationThe management of advanced supraglottic and
ORIGINAL ARTICLE ORGAN PRESERVATION FOR ADVANCED LARYNGEAL CARCINOMA Robert L. Foote, MD, 1 R. Tyler Foote, 1 Paul D. Brown, MD, 1 Yolanda I. Garces, MD, 1 Scott H. Okuno, MD, 2 Scott E. Strome, MD 3 1
More informationImplementation of the Dance Head and Neck Clinical Pathway
Implementation of the Dance Head and Neck Clinical Pathway Barbara Messing, MA, CCC-SLP, BCS-S, FASHA & Head and Neck Team GBMC Head and Neck Grand Rounds Acknowledgements Acknowledgements Background Evidence
More informationMANAGEMENT OF CA HYPOPHARYNX
MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable
More informationAccepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179
ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationSanguineti s (2)Comment: When it was initially published in 2003 with a median follow-up of 3.8 years (4), the RTOG study led to a change in
Commento di due Soci AIRO pubblicati su due prestigiose riviste internazionali al Trial della forastiere et al. Long term results of RTOG:91-11 (a cura di Dr. Russi e Dr. Testolin )! Forastiere)et)al.)Long/Term)Results)of)RTOG)91/11:)A)Comparison)of)
More informationConcurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
Original article Annals of Oncology 14: 1306 1311, 2003 DOI: 10.1093/annonc/mdg330 Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary A. Argiris
More informationRESEARCH ARTICLE. Swallowing Exercises: Will They Really Help Head and Neck Cancer Patients?
DOI:10.22034/APJCP.2018.19.3.797 RESEARCH ARTICLE Editorial Process: Submission:10/10/2017 Acceptance:02/12/2018 Swallowing Exercises: Will They Really Help Head and Neck Cancer Patients? Karim Mashhour
More informationLaryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
More informationFINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma
Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.
More informationSUPER-SUPRAGLOTTIC SWALLOW IN IRRADIATED HEAD AND NECK CANCER PATIENTS
SUPER-SUPRAGLOTTIC SWALLOW IN IRRADIATED HEAD AND NECK CANCER PATIENTS Jeri A. Logemann, PhD, 1 Barbara Roa Pauloski, PhD, 1 Alfred W. Rademaker, PhD, 2 Laura A. Colangelo, MS 2 1 Department of Communication
More informationSquamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations
Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Troy G. Scroggins Jr. MD Chairman, Department of Radiation Oncology Ochsner Health Systems 1 Association of Postoperative Radiotherapy
More informationTOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER
ORIGINAL ARTICLE TOXICITY OF TWO CISPLATIN-BASED RADIOCHEMOTHERAPY REGIMENS FOR THE TREATMENT OF PATIENTS WITH STAGE III/IV HEAD AND NECK CANCER Dirk Rades, MD, 1 Fabian Fehlauer, MD, 2 Mashid Sheikh-Sarraf,
More informationORIGINAL ARTICLE. Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer
ORIGINAL ARTICLE Examining the Need for Neck Dissection in the Era of Chemoradiation Therapy for Advanced Head and Neck Cancer Laura A. Goguen, MD; Marshall R. Posner, MD; Roy B. Tishler, MD, PhD; Lori
More informationMULTIPLE reports have. Prediction of Aspiration in Patients With Newly Diagnosed Untreated Advanced Head and Neck Cancer ORIGINAL ARTICLE
ORIGINAL ARTICLE Prediction of Aspiration in Patients With Newly Diagnosed Untreated Advanced Head and Neck Cancer Arie Rosen, MD; Thomas H. Rhee, MD; Rene Kaufman, MS, CCC-SLP Objectives: To determine
More informationGoals and Objectives: Head and Neck Cancer Service Department of Radiation Oncology
Goals and Objectives: Head and Neck Cancer Service Department of Radiation Oncology The head and neck cancer service provides training in the diagnosis, management, treatment, and follow-up care of head
More informationCetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina
More informationPersistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer
ORIGINAL ARTICLE Persistent tracheostomy after primary chemoradiation for advanced laryngeal or hypopharyngeal cancer Paul A. Tennant, MD, * Elizabeth Cash, PhD, Jeffrey M. Bumpous, MD, Kevin L. Potts,
More informationProspective subjective evaluation of swallowing function and dietary pattern in head and neck cancers treated with concomitant chemo-radiation
Original Article Free full text available from www.cancerjournal.net Prospective subjective evaluation of swallowing function and dietary pattern in head and neck cancers treated with concomitant chemo-radiation
More informationTitle. CitationInternational Journal of Clinical Oncology, 20(6): 1. Issue Date Doc URL. Rights. Type. File Information
Title Clinical outcomes of weekly cisplatin chemoradiother Sakashita, Tomohiro; Homma, Akihiro; Hatakeyama, Hir Author(s) Takatsugu; Iizuka, Satoshi; Onimaru, Rikiya; Tsuchiy CitationInternational Journal
More informationSimultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer
Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and
More informationAdjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support
Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no
More informationAccepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.
DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,
More informationSwallowing Disorders and Their Management in Patients with Multiple Sclerosis
National Multiple Sclerosis Society 733 Third Avenue New York, NY 10017-3288 Clinical Bulletin Information for Health Professionals Swallowing Disorders and Their Management in Patients with Multiple Sclerosis
More information2013 Charleston Swallowing Conference
Providing Quality Affordable Continuing Education and Treatment Materials for over 30 years. 2013 Charleston Swallowing Conference Session 9 Bedside Assessment: What Does It Tell You? 10:00 11:30 am Saturday,
More informationAnalysis of Dysphagia Patterns Using a Modified Barium Swallowing Test Following Treatment of Head and Neck Cancer
Original Article Yonsei Med J 2015 Sep;56(5):1221-1226 pissn: 0513-5796 eissn: 1976-2437 Analysis of Dysphagia Patterns Using a Modified Barium Swallowing Test Following Treatment of Head and Neck Cancer
More informationFUNCTIONAL ANALYSIS OF SWALLOWING OUTCOMES AFTER SUPRACRICOID PARTIAL LARYNGECTOMY
ORIGINAL ARTICLE FUNCTIONAL ANALYSIS OF SWALLOWING OUTCOMES AFTER SUPRACRICOID PARTIAL LARYNGECTOMY Jan S. Lewin, PhD, Katherine A. Hutcheson, MS, Denise A. Barringer, MS, Annette H. May, MA, Dianna B.
More informationQuality of life in patients treated for advanced hypopharyngeal or laryngeal cancer
European Annals of Otorhinolaryngology, Head and Neck diseases (2011) 128, 218 223 ORIGINAL ARTICLE Quality of life in patients treated for advanced hypopharyngeal or laryngeal cancer M. Guibert a, B.
More informationPercutaneous Endoscopic Gastrostomy Tube Dependence Following Chemoradiation in Head and Neck Cancer Patients
The Laryngoscope VC 2015 The American Laryngological, Rhinological and Otological Society, Inc. Percutaneous Endoscopic Gastrostomy Tube Dependence Following Chemoradiation in Head and Neck Cancer Patients
More informationClinical Swallowing Exam
Clinical Evaluation Template 1 Clinical Exam Name: ID/Medical record number: Date of exam: Referred by: Reason for referral: Medical diagnosis: Date of onset of diagnosis: Other relevant medical history/diagnoses/surgery
More informationPharyngoesophageal Strictures in Head and Neck Cancer
Pharyngoesophageal Strictures in Head and Neck Cancer Barbara P. Messing, M.A., CCC-SLP, BRS-S, S, John Saunders, M.D., Patrick K. Ha, M.D., Marshall Levine, M.D., Ray Blanco, M.D., Eva Zinreich, M.D.,
More informationThe following slides are from a. presentation given by. H. Worth Boyce, M.D. on. Specialized Studies on Diseases of the Esophagus.
The following slides are from a presentation given by H. Worth Boyce, M.D. on Endoscopic Lumen Restoration at the 8 th OESO World Organization for Specialized Studies on Diseases of the Esophagus. Endoscopic
More informationJamie L Penner, Susan E McClement, Jo-Ann V Sawatzky
Clinical review Management of dysphagia in advanced cancer Jamie L Penner, Susan E McClement, Jo-Ann V Sawatzky Abstract Individuals with advanced cancer often experience dysphagia as a result of their
More informationFeeding and Oral Hygiene: How to Address the Challenges
Feeding and Oral Hygiene: How to Address the Challenges Paige W. Roberts, OTR/L Occupational Therapist Pediatric Feeding Disorders Program Marcus Autism Center Disclaimer: This content is for personal
More informationEndoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia Difficulty
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationRADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.
RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL
More informationORIGINAL ARTICLE. Video Fluoroscopic Evaluation After Glossectomy
ORIGINAL ARTICLE Video Fluoroscopic Evaluation Glossectomy Cristina Lemos Barbosa Furia, SP; Elisabete Carrara-de Angelis, SP; Nívia Maria Silva Martins, SP; Ana Paula Brandão Barros, SP; Benjamin Carneiro,
More informationThomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX
Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21
More informationFactors predicting suitability of organ preservation with radiation therapy in laryngeal and hypopharyngeal cancer
ORIGINAL ARTICLE Factors predicting suitability of organ preservation with radiation therapy in laryngeal and hypopharyngeal cancer Parul N. Barry 1, Adrianna L. Henson 1, Nicole E. Goodwin 2, Elizabeth
More information15/11/2011. Swallowing
Swallowing Swallowing starts from placement of the food in the mouth and continues until food enters the stomach. Dysphagia: any difficulty in moving food from mouth to stomach. Pharynx is shared for both
More informationComparative study of Gemcitabine versus Cisplatin concurrent with radiotherapy for locally advanced head and neck cancer
Journal of Cancer Treatment and Research 2014; 2(4): 37-44 Published online August 30, 2014 (http://www.sciencepublishinggroup.com/j/jctr) doi: 10.11648/j.jctr.20140204.12 Comparative study of Gemcitabine
More informationVIDEOFLUOROSCOPIC SWALLOWING EXAM
VIDEOFLUOROSCOPIC SWALLOWING EXAM INDENTIFYING INFORMATION May include the following: Name, ID/medical record number, date of birth, date of exam, referred by, reason for referral HISTORY/SUBJECTIVE INFORMATION
More informationORIGINAL ARTICLE. Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation
ORIGINAL ARTICLE Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck for Organ Preservation and Palliation Michael E. Poole, PA-C, MPH; Scott L. Sailer, MD; Julian G. Rosenman,
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER
ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4
More informationSWALLOWING DIFFICULTIES IN HD
Nutrition, eating and swallowing needs, challenges and solutions Workshop SWALLOWING DIFFICULTIES IN HD Angela Nuzzi Speech and Language Pathologist (SLP) EHDN Language Coordinator - Italy The role of
More informationKey words: Head-and-neck cancer, Chemoradiation, Concomitant Boost Radiation, Docetaxel. Materials and Methods
Weekly Cisplatin and Docetaxel plus Concomitant Boost Concurrently with Radiation Therapy in the Treatment of Locally Advanced Head And Neck Cancer: Phase II Trial Abd El Halim Abu-Hamar, MD 1, Naser Abd
More informationDysphagia in Tongue Cancer Patients Yu Ri Son, MD, Kyoung Hyo Choi, MD, PhD, Tae Gyun Kim, MD
Original Article Ann Rehabil Med 2015;39(2):210-217 pissn: 2234-0645 eissn: 2234-0653 http://dx.doi.org/10.5535/arm.2015.39.2.210 Annals of Rehabilitation Medicine Dysphagia in Tongue Cancer Patients Yu
More informationUse of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. American Society of Clinical Oncology Clinical Practice Guideline
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer American Society of Clinical Oncology Clinical Practice Guideline Introduction ASCO convened an Expert Panel to develop recommendations
More informationAspiration pneumonia after chemo intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors
ORIGINAL ARTICLE Aspiration pneumonia after chemo intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors Klaudia U. Hunter, MD, 1 Oliver E. Lee,
More informationORIGINAL ARTICLE. Variables Associated With Feeding Tube Placement in Head and Neck Cancer. cases of head and neck cancer
ORIGINAL ARTICLE Variables Associated With Feeding Tube Placement in Head and Neck Cancer Sara S. Cheng, MD, PhD; Jeffrey E. Terrell, MD; Carol R. Bradford, MD; David L. Ronis, PhD; Karen E. Fowler, MPH;
More informationAnalyzing Swallow Studies in Pediatrics
Analyzing Swallow Studies in Pediatrics About the Speaker Robert Beecher, M.S., CCC-SLP was formerly senior speech-language pahologist at the Children's Hospital of Wisconsin in Milwaukee. He is specialized
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationDaniels SK & Huckabee ML (2008). Dysphagia Following Stroke. Muscles of Deglutition. Lateral & Mesial Premotor Area 6. Primary Sensory
An Overview of Dysphagia in the Stroke Population Stephanie K. Daniels, PhD Michael E. DeBakey VA Medical Center PM & R, Baylor College of Medicine Communication Sciences and Disorders, University of Houston
More informationDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston Texas.
ORIGINAL ARTICLE Gastrostomy tube placement in patients with oropharyngeal carcinoma treated with radiotherapy or chemoradiotherapy: Factors affecting placement and dependence Mihir K. Bhayani, MD, Katherine
More informationComparison of acute toxicities of two chemotherapy schedules for head and neck cancers
Original Article Free full text available from www.cancerjournal.net Comparison of acute toxicities of two chemotherapy schedules for head and neck cancers Geeta SN, TK Padmanabhan, J Samuel, K Pavithran*,
More informationAccepted 4 April 2014 Published online 6 April 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI /hed.23708
ORIGINAL ARTICLE Impact of transcutaneous neuromuscular electrical stimulation on dysphagia in patients with head and neck cancer treated with definitive chemoradiation Aashish D. Bhatt, MD, 1 Nicole Goodwin,
More informationBEAVERTAIL MODIFICATION OF THE RADIAL FOREARM FREE FLAP IN BASE OF TONGUE RECONSTRUCTION: TECHNIQUE AND FUNCTIONAL OUTCOMES
ORIGINAL ARTICLE BEAVERTAIL MODIFICATION OF THE RADIAL FOREARM FREE FLAP IN BASE OF TONGUE RECONSTRUCTION: TECHNIQUE AND FUNCTIONAL OUTCOMES Hadi Seikaly, MD, FRCSC, 1,2 Jana Rieger, PhD, 2 Daniel O Connell,
More informationSwallowing Screen Why? How? and So What? พญ.พวงแก ว ธ ต สก ลช ย ภาคว ชาเวชศาสตร ฟ นฟ คณะแพทยศาสตร ศ ร ราชพยาบาล
Swallowing Screen Why? How? and So What? พญ.พวงแก ว ธ ต สก ลช ย ภาคว ชาเวชศาสตร ฟ นฟ คณะแพทยศาสตร ศ ร ราชพยาบาล Dysphagia in Stroke The incidence of dysphagia after stroke ranging from 23-50% 1 Location
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationWhat is head and neck cancer? How is head and neck cancer diagnosed and evaluated? How is head and neck cancer treated?
Scan for mobile link. Head and Neck Cancer Head and neck cancer is a group of cancers that start in the oral cavity, larynx, pharynx, salivary glands, nasal cavity or paranasal sinuses. They usually begin
More informationTREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy
TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park
More information5/20/ ) Haffty GB: Concurrent chemoradiation in the treatment of head and neck cancer. Hematol. Oncol. Clin: North Am.
Prague, 24-25 25 April 29 ALTERNATING CHEMORADIATION: FOR WHOM? M. Merlano MD Holy Cross Gen. Hospital Cuneo - Italy ALTERNATING CHEMORADIATION: FOR WHOM? Definition of alternating chemoradiation Targets
More informationTitle. CitationJournal of Oral and Maxillofacial Surgery, 70(11): 2. Issue Date Doc URL. Type. File Information
Title Does Swallowing Function Recover in the Long Term in Author(s)Tei, Kanchu; Sakakibara, Noriyuki; Yamazaki, Yutaka; CitationJournal of Oral and Maxillofacial Surgery, 70(11): 2 Issue Date 2012-11
More informationAccepted 1 August 2008 Published online 23 December 2008 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE EFFECT OF INDUCTION CHEMOTHERAPY ON SPEECH AND SWALLOWING FUNCTION IN PATIENTS WITH ORAL TONGUE CANCER Denise A. Barringer, MS, 1 Katherine A. Hutcheson, MS, 1 Erich M. Sturgis, MD, MPH,
More informationAdherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients
ORIGINAL ARTICLE Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients Eileen Huh Shinn, PhD, 1 * Karen Basen-Engquist, PhD, 1 George Baum,
More informationORIGINAL ARTICLE. Harold Lau, MD; Tien Phan, MD; Jack MacKinnon, MD; T. Wayne Matthews, MD
ORIGINAL ARTICLE Absence of Planned Neck Dissection for the N2-N3 Neck After Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Harold Lau, MD; Tien Phan, MD; Jack MacKinnon,
More informationORIGINAL ARTICLE. Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx
ORIGINAL ARTICLE Salvage Surgery After Failure of Nonsurgical Therapy for Carcinoma of the Larynx and Hypopharynx Sandro J. Stoeckli, MD; Andreas B. Pawlik, MD; Margareta Lipp, MD; Alexander Huber, MD;
More informationPharyngeal Effects of Bolus Volume, Viscosity, and Temperature in Patients With Dysphagia Resulting From Neurologic Impairment and in Normal Subjects
Journal of Speech and Hearing Research, Volume 37, 1041-1049, October 1994 Pharyngeal Effects of Bolus Volume, Viscosity, and Temperature in Patients With Dysphagia Resulting From Neurologic Impairment
More informationORIGINAL ARTICLE. Swallowing after non-surgical treatment (radiation therapy / radiochemotherapy protocol) of laryngeal cancer
Braz J Otorhinolaryngol. 2011;77(1):96-101. ORIGINAL ARTICLE BJORL Swallowing after non-surgical treatment (radiation therapy / radiochemotherapy protocol) of laryngeal cancer Juliana Portas 1, Claudia
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationFLOOVIDEOFLUOROSCOPIC SWALLOW STUDIES: LOOKING BEYOND ASPIRATION. Brenda Sitzmann, MA, CCC-SLP (816)
FLOOVIDEOFLUOROSCOPIC SWALLOW STUDIES: LOOKING BEYOND ASPIRATION Brenda Sitzmann, MA, CCC-SLP bksitzmann@cmh.edu (816) 302-8037 DISCLOSURES Ms. Sitzmann is speech-language pathologist at Children s Mercy
More informationLate Oropharyngeal Dysphagia Following Head and Neck Cancer Treatment ASHA 2014 Orlando, FL
Late Oropharyngeal Dysphagia Following Head and Neck Cancer Treatment ASHA 2014 Orlando, FL Vicki Lewis, M.A., CCC SLP Disclosure No financial interests to disclose The Disney analogy; sort of Patient
More informationNew Evidence-Based Support of a 3 Ounce Water Swallow Challenge Protocol
New Evidence-Based Support of a 3 Ounce Water Swallow Challenge Protocol Steven B. Leder, Ph.D. Yale University School of Medicine New Haven, Connecticut Debra M. Suiter, Ph.D. VA Medical Center-Memphis
More informationThe Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review
The Role of Concurrent Chemo-radiotherapy in Patients with Head and Neck Cancers: A Review M.D. Al-Sarraf 1 1 Williams Beaumont Hospital, Royal Oak, Michigan, USA Introduction In the past, radiotherapy
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationHypopharyngeal Squamous Cell Carcinoma: Three-Dimensional or Intensity-Modulated Radiotherapy? A Single Institution s Experience
The Laryngoscope VC 2015 The American Laryngological, Rhinological and Otological Society, Inc. Hypopharyngeal Squamous Cell Carcinoma: Three-Dimensional or Intensity-Modulated Radiotherapy? A Single Institution
More informationSurgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma
Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,
More informationLymph node ratio as a prognostic factor in head and neck cancer patients
Chen et al. Radiation Oncology (2015) 10:181 DOI 10.1186/s13014-015-0490-9 RESEARCH Open Access Lymph node ratio as a prognostic factor in head and neck cancer patients Chien-Chih Chen 1*, Jin-Ching Lin
More informationLong Term Toxicities of Head & Neck Cancer Therapies. Faith Mutale Abramson Cancer Center University of Pennsylvania
Long Term Toxicities of Head & Neck Cancer Therapies Faith Mutale Abramson Cancer Center University of Pennsylvania Head & Neck Cancer 2-3% of all cancers 1-2% of all cancer deaths Incidence includes:
More informationHEAD AND NECK CANCER TREATMENT REGIMENS (Part 1 of 5)
HEAD AND NECK CANCER TREATMENT S (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network (NCCN) recommends cancer patient participation in clinical trials as the gold standard for treatment.
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationIntroduction. Rico N. Rinkel 1 Irma M. Verdonck-de Leeuw. Jan Buter 3 Remco de Bree. C. René Leemans 1
Eur Arch Otorhinolaryngol (2016) 273:1849 1855 DOI 10.1007/s00405-015-3680-z HEAD AND NECK Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based
More informationReluctance or refusal to feed or eat. Understanding Feeding Aversion in a City Full of Foodies. Presentation Outline. Learning Objectives
Understanding Feeding Aversion in a City Full of Foodies Amy Houtrow, MD, MPH Pediatric Physical Medicine & Rehabilitation UCSF Department of Pediatrics June 2, 2007 Learning Objectives Learners will be
More informationBidirectional esophageal dilatation in pharyngoesophageal stenosis postradiotherapy
OPERATIVE TECHNIQUES PICTORIAL ESSAY Bidirectional esophageal dilatation in pharyngoesophageal stenosis postradiotherapy Haim Gavriel, MD,* Cuong Duong, MB, BS, PhD, FRACS, John Spillane, MB, BS, FRACS,
More informationNICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36
Cancer of the upper aerodigestive e tract: assessment and management in people aged 16 and over NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng36 NICE 2018. All rights reserved. Subject
More informationGourin et al.: Long-Term Outcomes of Larynx Cancer Care in the Elderly
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. Short- and Long-Term Outcomes of Laryngeal Cancer Care in the Elderly Christine G. Gourin, MD, MPH; Heather
More informationBolus effects on patient awareness of swallowing difficulty and swallow physiology after chemoradiation for head and neck cancer
ORIGINAL ARTICLE Bolus effects on patient awareness of swallowing difficulty and swallow physiology after chemoradiation for head and neck cancer Nicole M. Rogus-Pulia, PhD, CCC-SLP, 1* Margaret Pierce,
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More information